FilingSEC EDGAR8-K
X4 Pharmaceuticals Shares Clinical Progress at Investor Day
· SEC accepted
StageInvestor Day
Filing content
The company shared updates at its Investor Day, confirming plans for full enrollment of the 4WARD Phase 3 trial by year-end and topline data in Q1 2028.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…